Skip to content
Bamboo WorksBamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Inhaled vaccine

CanSino Biologics announced on Wednesday it recorded a net loss of 1.28 billion yuan in the first half of this year, reversing a 16.04 million yuan profit in the same period of 2022.

FAST NEWS: CanSino’s revenue plunges as demand dries up for Covid vaccines

The latest: CanSino Biologics Inc. (6185.HK; 688185.SH) announced on Wednesday it recorded a net loss of 1.28 billion yuan ($176 million) in the first half of this year, reversing a 16.04…
August 31, 2023
6185.HK 688185.SHG

FAST NEWS: CanSino’s Inhaled Covid Booster Gets China Green Light

The latest: CanSino Biologics Inc. (6185.HK; 688185.SH) announced on Sunday that China’s National Medical Products Administration (NMPA) have given emergency use authorization for its inhaled recombinant Covid-19 vaccine for use as…
September 6, 2022

Recent Articles

CanSino Biologics announced on Wednesday it recorded a net loss of 1.28 billion yuan in the first half of this year, reversing a 16.04 million yuan profit in the same period of 2022.
August 31, 2023

FAST NEWS: CanSino’s revenue plunges as demand dries up for Covid vaccines

6185.HK 688185.SHG
September 6, 2022

FAST NEWS: CanSino’s Inhaled Covid Booster Gets China Green Light

RECENT ARTICLES

  1. Clover Biopharmaceuticals Ltd. faces a potentially damaging fight
    April 3, 2025
    Dispute over Covid vaccines casts doubt on Clover Bio recovery
    2197.HK
  2. January 20, 2025
    Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
    ZYBT.US
  3. March 25, 2025
    Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  4. January 16, 2025
    WuXi Biologics sells vaccine plant as new U.S. law looms
    2269.HK
  5. February 17, 2025
    Yan Palace flies back to profit growth as revenue sags
    1497.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.